Literature DB >> 33371259

Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer.

Hung-Yu Lin1, Chia-Jung Li2,3, Ya-Ling Yang4, Ying-Hsien Huang5, Ya-Tze Hsiau6, Pei-Yi Chu6,7,8,9.   

Abstract

The lysyl oxidase (LOX) family members are secreted copper-dependent amine oxidases, comprised of five paralogues: LOX and LOX-like l-4 (LOXL1-4), which are characterized by catalytic activity contributing to the remodeling of the cross-linking of the structural extracellular matrix (ECM). ECM remodeling plays a key role in the angiogenesis surrounding tumors, whereby a corrupt tumor microenvironment (TME) takes shape. Primary liver cancer includes hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), ranked as the seventh most common cancer globally, with limited therapeutic options for advanced stages. In recent years, a growing body of evidence has revealed the key roles of LOX family members in the pathogenesis of liver cancer and the shaping of TME, indicating their notable potential as therapeutic targets. We herein review the clinical value and novel biological roles of LOX family members in tumor progression and the TME of liver cancers. In addition, we highlight recent insights into their mechanisms and their potential involvement in the development of target therapy for liver cancer.

Entities:  

Keywords:  cholangiocarcinoma; hepatocellular carcinoma; liver cancer; lysyl oxidase family members; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33371259      PMCID: PMC7766343          DOI: 10.3390/ijms21249751

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  106 in total

1.  Identification of functional hypoxia inducible factor response elements in the human lysyl oxidase gene promoter.

Authors:  Victoria Wang; David A Davis; Robert Yarchoan
Journal:  Biochem Biophys Res Commun       Date:  2017-06-15       Impact factor: 3.575

2.  Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.

Authors:  Vivian Barry-Hamilton; Rhyannon Spangler; Derek Marshall; Scott McCauley; Hector M Rodriguez; Miho Oyasu; Amanda Mikels; Maria Vaysberg; Haben Ghermazien; Carol Wai; Carlos A Garcia; Arleene C Velayo; Brett Jorgensen; Donna Biermann; Daniel Tsai; Jennifer Green; Shelly Zaffryar-Eilot; Alison Holzer; Scott Ogg; Dung Thai; Gera Neufeld; Peter Van Vlasselaer; Victoria Smith
Journal:  Nat Med       Date:  2010-09-05       Impact factor: 53.440

3.  Lysyl oxidase, extracellular matrix remodeling and cancer metastasis.

Authors:  Qian Xiao; Gaoxiang Ge
Journal:  Cancer Microenviron       Date:  2012-04-13

4.  TGF-β1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking.

Authors:  Zakaria Ezzoukhry; Elodie Henriet; Léo Piquet; Kevin Boyé; Paulette Bioulac-Sage; Charles Balabaud; Gabrielle Couchy; Jessica Zucman-Rossi; Violaine Moreau; Frédéric Saltel
Journal:  Eur J Cell Biol       Date:  2016-10-04       Impact factor: 4.492

5.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

6.  Association between lysyl oxidase G473A polymorphism and ovarian cancer in the Han Chinese population.

Authors:  X Wang; J-L Cong; L-Y Qu; L Jiang; Y Wang
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

7.  Expression of the lysyl oxidase propeptide in hepatocellular carcinoma and its clinical relevance.

Authors:  Ying Zheng; Xuemei Wang; Haidong Wang; Wei Yan; Quan Zhang; Xin Chang
Journal:  Oncol Rep       Date:  2014-02-20       Impact factor: 3.906

8.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

9.  Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.

Authors:  Damien Bergeat; Alain Fautrel; Bruno Turlin; Aude Merdrignac; Michel Rayar; Karim Boudjema; Cédric Coulouarn; Laurent Sulpice
Journal:  J Surg Res       Date:  2016-03-26       Impact factor: 2.192

10.  Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.

Authors:  Naoki Ikenaga; Zhen-Wei Peng; Kahini A Vaid; Susan B Liu; Shuhei Yoshida; Deanna Y Sverdlov; Amanda Mikels-Vigdal; Victoria Smith; Detlef Schuppan; Yury V Popov
Journal:  Gut       Date:  2017-01-10       Impact factor: 23.059

View more
  10 in total

1.  Exosomal microRNA-551b-3p from bone marrow-derived mesenchymal stromal cells inhibits breast cancer progression via regulating TRIM31/Akt signaling.

Authors:  Ziang Yang; Bei Xu; Sheng Wu; Weige Yang; Rongkui Luo; Shengkai Geng; Zhaochen Xin; Wen Jin; Xiong Shen; Xixi Gu; Hongwei Zhang; Hong Wang
Journal:  Hum Cell       Date:  2022-08-09       Impact factor: 4.374

2.  BMSCs overexpressed ISL1 reduces the apoptosis of islet cells through ANLN carrying exosome, INHBA, and caffeine.

Authors:  Ying Wang; Jiang-Wei Zhang; Jing-Wen Wang; Jia-Le Wang; Shu-Cong Zhang; Rui-Yang Ma; Jing Zhang; Yang Li; Pei-Jun Liu; Wu-Jun Xue; Jin Zheng; Xiao-Ming Ding
Journal:  Cell Mol Life Sci       Date:  2022-10-03       Impact factor: 9.207

3.  A Co-Expression Network Reveals the Potential Regulatory Mechanism of lncRNAs in Relapsed Hepatocellular Carcinoma.

Authors:  Yuan Fang; Yang Yang; XiaoLi Zhang; Na Li; Bo Yuan; Li Jin; Sheng Bao; MengGe Li; Dan Zhao; LingRui Li; Zhong Zeng; HanFei Huang
Journal:  Front Oncol       Date:  2021-08-31       Impact factor: 6.244

4.  Relationship between plasma cell-free DNA changes and lysyl oxidase during the treatment and prognosis of canine transmissible venereal tumors.

Authors:  Mona Mohamadzaheri; Hadi Cheraghi; Darioush Shirani; Ali Hatamkhani
Journal:  BMC Vet Res       Date:  2022-02-21       Impact factor: 2.741

5.  Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis.

Authors:  Chenyu Sun; Shaodi Ma; Yue Chen; Na Hyun Kim; Sujatha Kailas; Yichen Wang; Wenchao Gu; Yisheng Chen; John Pocholo W Tuason; Chandur Bhan; Nikitha Manem; Yuting Huang; Ce Cheng; Zhen Zhou; Qin Zhou; Yanzhe Zhu
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

6.  The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer.

Authors:  Xiao Guan; Na Lu; Jianping Zhang
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

7.  MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA.

Authors:  Ya-Ling Yang; Ming-Chao Tsai; Yen-Hsiang Chang; Chen-Chen Wang; Pei-Yi Chu; Hung-Yu Lin; Ying-Hsien Huang
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

Review 8.  New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics.

Authors:  Ya-Ling Yang; Yen-Hsiang Chang; Chia-Jung Li; Ying-Hsien Huang; Ming-Chao Tsai; Pei-Yi Chu; Hung-Yu Lin
Journal:  J Pers Med       Date:  2021-03-18

9.  lncRNA/miR-29c-Mediated High Expression of LOX Can Influence the Immune Status and Chemosensitivity and Can Forecast the Poor Prognosis of Gastric Cancer.

Authors:  Aitao Nai; Huihui Zeng; Qiong Wu; Zirui He; Shuwen Zeng; Shoaib Bashir; Feng Ma; Jie He; Wei Wan; Meng Xu
Journal:  Front Cell Dev Biol       Date:  2022-01-03

10.  A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.

Authors:  Yiyang Tang; Yanqin Wu; Miao Xue; Bowen Zhu; Wenzhe Fan; Jiaping Li
Journal:  J Oncol       Date:  2022-01-24       Impact factor: 4.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.